*Please note: this recording is not approved for CE credits
This lecture will discuss how the SGLT2 inhibitors are being used in the management of laminitis, hyperinsulinaemia and weight loss with their potential benefits and harms highlighted. Recent publications will be reviewed along with recent unpublished work.
0:35 Intro
5:20 SGLT2 historical background
7:59 What do we know about SGLTs?
11:17 SGLT2 vs SGLT1
18:27 SGLT2s and weightloss
20:02 SGLT2s and cardiovascular and renal
22:37 SGLT2 potential benefits in horses
23:49 SGLT inhibitors in horses
28:29 Managing obesity and hyperinsulinemia
32:00 Obesity, hyperinsulinemia and laminitis
38:36 Pharmaceuticals to limit hyperinsulinemia
41:36 Ertugliflozin and obesity
41:56 Triglyceride responses to ertugliflozin
42:44 Long-term use of ertugliflozin in horses
43:20 Half-dose ertugliflozin in horses
48:48 Vet survey on ertugliflozin
50:46 Ertugliflozin or canagliflozin for horses
55:00 Ertugliflozin case studies with video evidence
57:23 Take home messages
1:00:00 Q&A
EMT Consulting
We have a full library of webinars and other resources to help you continue learning about the topics important to you, your practice, and your patients!
Contact Us
More to Explore
All information provided on this site is for educational purposes only. Every effort has been made to provide accurate and up-to-date information. It is not intended to be used as medical advice for the diagnosis of health problems nor does it include all possible uses, actions, safety measures, side effects, or interactions. Please consult a healthcare provider or veterinarian for the diagnosis and treatment of any health conditions. Epicur Pharma® manufactured veterinary orders are for non food chain animals only. Epicur Pharma® is registered with the FDA as an outsourcing facility.
FDA-Registered 503B Outsourcing Facility
A Stokes Healthcare Company
© 2024 Epicur Pharma®
Following graduation from The University of Bristol in 2001, David worked in farm animal and equine practice in Somerset, UK before and completing an internship at Liphook Equine Hospital. A 3-year Horserace Betting Levy Board residency at The University of Glasgow and Liphook Equine Hospital enabled him to train as a specialist in equine internal medicine and to gain a masters by research into equine asthma and an RCVS certificate in equine medicine. David spent a number of years at Liphook Equine Hospital and had spells at The Royal Veterinary College and Charles Sturt University in Australia before moving to Rainbow Equine Hospital in Yorkshire where he became a director. David returned to his Westcountry roots in 2020 and now works as an independent equine medicine and therapeutics consultant. He is a Past President of the British Equine Veterinary Association, former chair of their health and medicines committee and sits on a number of equine industry advisory groups. David has an active research interest in equine endocrinology and gastroenterology and speaks regularly internationally.